Mycophenolate mofetil
Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds: > Other: > Other: > Aromatic or modified aromatic: > Mycophenolate mofetil
Duty Rate (from China)
Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Products classified under HTS 2934.99.01.00
Mycophenolate Mofetil Hydrochloride
Mycophenolate mofetil hydrochloride is the hydrochloride salt form of mycophenolate mofetil, a semi-synthetic immunosuppressant derived from mycophenolic acid with a morpholinoethyl ester group. It falls under HTS 2934.99.01.00 as a specific aromatic heterocyclic compound used primarily to prevent organ transplant rejection by inhibiting lymphocyte proliferation. This chemically defined compound contains a fused heterocyclic ring system characteristic of Chapter 29 heading 2934.
Mycophenolate Mofetil Free Base Powder
Pure mycophenolate mofetil free base in pharmaceutical-grade powder form serves as the active pharmaceutical ingredient (API) for generic immunosuppressant production. Classified under HTS 2934.99.01.00 as the specific aromatic heterocyclic compound, it features the characteristic morpholinoester structure on the mycophenolic acid backbone. Used exclusively in manufacturing formulations for preventing organ rejection.
Pharmaceutical Grade Mycophenolate Mofetil USP
Mycophenolate mofetil meeting United States Pharmacopeia (USP) standards for use in FDA-approved generic drug manufacturing. This specific aromatic heterocyclic immunosuppressant falls under HTS 2934.99.01.00 per Chapter 29 notes for chemically defined organic compounds. The product's fused ring system with ester functionality defines its precise tariff classification.
Mycophenolate Mofetil EP Reference Standard
European Pharmacopoeia reference standard of mycophenolate mofetil used for analytical method validation and quality control testing. As a chemically defined aromatic heterocyclic compound, it precisely matches HTS 2934.99.01.00 specifications. Supplied in certified amounts (typically 100mg vials) for HPLC/GC calibration.
Bulk Mycophenolate Mofetil API for Generic Production
Large-quantity bulk API mycophenolate mofetil specifically manufactured for generic pharmaceutical production of transplant rejection medications. Falls under HTS 2934.99.01.00 as the named aromatic heterocyclic compound per Chapter 29 legal notes. Chemically defined with specific morpholinoethyl ester structure distinguishing from other mycophenolic derivatives.
Mycophenolate Mofetil Morpholino Ester
The specific morpholinoethyl ester prodrug form of mycophenolic acid, chemically defined as mycophenolate mofetil under HTS 2934.99.01.00. This aromatic heterocyclic compound converts in vivo to active mycophenolic acid via esterase cleavage. Essential API for branded CellCept® and generic equivalents.
Sterile Mycophenolate Mofetil for Injection Formulation
Sterile-grade mycophenolate mofetil powder intended for IV injection formulation after further processing. Classified under HTS 2934.99.01.00 as bulk aromatic heterocyclic API despite sterile processing, per Chapter 29 notes excluding only finished medicaments. Meets parenteral quality standards with endotoxin limits <0.5 EU/mg.
Mycophenolate Mofetil Working Standard
Certified working standard mycophenolate mofetil for routine HPLC assay calibration and stability testing in pharmaceutical quality control laboratories. As a pure chemically defined aromatic heterocyclic compound, precisely matches HTS 2934.99.01.00. Supplied with assigned content value traceable to primary standards.
GMP Manufactured Mycophenolate Mofetil
Mycophenolate mofetil produced under Good Manufacturing Practice (GMP) conditions for commercial generic drug production. Specific aromatic heterocyclic compound classified under HTS 2934.99.01.00 per Chapter 29 for bulk chemically defined organic pharmaceuticals. Full process validation and three-stage purification ensure regulatory compliance.